Search Result

Results for "

LNCap

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (3) ADC Cytotoxin (1) Akt (3) Aldehyde Dehydrogenase (ALDH) (1) AMPK (2) Androgen Receptor (45) Antibiotic (1) Apoptosis (22) Atg4 (1) Autophagy (5) AUTOTACs (1) Bacterial (1) c-Myc (1) Cannabinoid Receptor (1) Caspase (2) Cathepsin (1) CDK (1) COX (1) CXCR (1) Deubiquitinase (1) DNA Stain (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (2) Epigenetic Reader Domain (9) Estrogen Receptor/ERR (1) FAK (1) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (2) Fungal (2) HDAC (4) Histone Acetyltransferase (5) Histone Demethylase (5) Histone Methyltransferase (1) HIV (7) HSP (1) IGF-1R (1) Integrin (1) Isotope-Labeled Compounds (2) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (3) MAGL (1) MDM-2/p53 (1) MNK (1) Molecular Glues (2) Monoamine Oxidase (3) mTOR (6) NF-κB (1) NO Synthase (1) p38 MAPK (1) PARP (1) PGE synthase (1) Phosphatase (1) Phospholipase (2) PI3K (4) PKC (2) PKD (1) PROTAC Linkers (1) PROTACs (8) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (1) Reverse Transcriptase (6) ROR (2) Src (2) STAT (1) Telomerase (6) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (128) Cardiovascular Disease (1) Endocrinology (2) Infection (13) Inflammation/Immunology (9) Metabolic Disease (3)
Click Chemistry:	PROTAC Synthesis (1)

141

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70002

Enzalutamide Maximum Cited Publications 154 Publications Verification MDV3100	Androgen Receptor Autophagy	Cancer
Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .

HY-70002S1

Enzalutamide-d6 MDV3100-d₆	Androgen Receptor	Cancer
Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-70002S

Deutenzalutamide Enzalutamide-d₃; MDV3100-d₃	Androgen Receptor Autophagy	Cancer
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-126464

Estromustine EoM	Androgen Receptor	Cancer
Estromustine (EoM) is the active metabolite of Estramustine phosphate (HY-13627A). Estromustine binds to mutant androgen receptor (m-AR) with EC₅₀ of 2.6 μM in LNCaP, exhibits cytotoxicity in human prostate cells LNCaP with IC₅₀ of 9.73 μM .

HY-131953

Androgen receptor-IN-3	Androgen Receptor	Cancer
Androgen receptor-IN-3 (Compound 22) is an androgen receptor inhibitor. Androgen receptor-IN-3 inhibits AR-driven transcriptional activity in LNCaP cells, with an IC₅₀ of 5.04 μM .

HY-70002R

Enzalutamide (Standard)	Androgen Receptor Autophagy	Cancer
Enzalutamide (Standard) is the analytical standard of Enzalutamide. This product is intended for research and analytical applications. Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .

HY-163641

AR Degrader-1	Molecular Glues Androgen Receptor E1/E2/E3 Enzyme	Cancer
AR Degrader-1 (Compound ML 2-9) is a molecular glue androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR through DCAF16 (E3 ligase) without obvious cytotoxicity in LNCaP prostate cancer cells .

HY-146494

Androgen receptor antagonist 5	Androgen Receptor	Cancer
Androgen receptor antagonist 5 (compound 42f) is a potent androgen receptor (AR) antagonist with an IC₅₀ value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer .

HY-162023

mTOR inhibitor-10	mTOR PI3K	Cancer
mTOR inhibitor-10 (Compound 9c) is a selective inhibitor for mTOR. mTOR inhibitor-10 inhibits mTOR and PI3K-α, with IC₅₀ of 0.7 and 825 nM. mTOR inhibitor-10 inhibits proliferation of LNCaP with IC₅₀ of 87 nM .

HY-N10265

Stephacidin B	Endogenous Metabolite	Cancer
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells .

HY-150268

BET-IN-16	Epigenetic Reader Domain	Cancer
BET-IN-16 (Comp I) is a BET inhibitor. BET-IN-16 shows anticancer activity. BET-IN-16 inhibits prostate cancer cell growth, with IC₅₀ values of 0.043 and 0.034 μM against LNCaP and 22Rv1 cells, respectively .

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

HY-162025

mTOR inhibitor-17	mTOR PI3K	Cancer
mTOR inhibitor-17 (Compound 9e) is a selective inhibitor for mTOR. mTOR inhibitor-10 inhibits mTOR and PI3K-α, with IC₅₀ of 0.68 and 1359 nM. mTOR inhibitor-10 inhibits proliferation of LNCaP with IC₅₀ of 40 nM .

HY-162024

mTOR inhibitor-16	mTOR PI3K	Cancer
mTOR inhibitor-16 (Compound 9f) is a selective inhibitor for mTOR. mTOR inhibitor-10 inhibits mTOR and PI3K-α, with IC₅₀ of 1.25 and 82 nM. mTOR inhibitor-10 inhibits proliferation of LNCaP with IC₅₀ of 140 nM .

HY-N12124

Monascuspiloin Monascinol	Akt mTOR AMPK Androgen Receptor Apoptosis Autophagy	Cancer
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice .

HY-17548

VMY-1-103	Caspase Apoptosis	Cancer
VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondrial membrane potential, induces p53 phosphorylation and and PARP cleavage, activates caspase-3, and thus induces apoptosis in prostate cancer cell LNCaP .

HY-153772

Androgen receptor antagonist 8	Androgen Receptor	Cancer
Androgen receptor antagonist 8 (Example 13) is an androgen receptor antagonist. Androgen receptor antagonist 8 inhibits prostate specific antigen secretion in LNcap cell (IC₅₀: 88 nM). Androgen receptor antagonist 8 can be used for prostate cancer research .

HY-149914

WCA-814	Androgen Receptor	Cancer
WCA-814 is an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate. WCA-814 induces the degradation of full-length and AR-V7. WCA-814 has cytotoxic effect in prostatic cancer cells (IC₅₀: 171.2 nM, 26.5 nM for LNCaP, 22Rv1 cell) .

HY-N2733

7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin	Others	Others
7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin is a coumarin, that can be isolated from campylotropis hirtella (FRANCH.) SCHINDL. 7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin inhibits PSA secretion in LNCaP cells, with an IC₅₀ of 24.2 μg/mL .

HY-129672

Thelenotoside B 25-Dihydrostichorrenoside E	Others	Cancer
Thelenotoside B (25-Dihydrostichorrenoside E) shows strong cytotoxicities against five cancer cell lines as HepG2, KB, LNCaP, MCF7 and SK-Mel2 with the IC₅₀ values from 0.95 ± 0.08 to 1.90 ± 0.13 μM. Thelenotoside B is a triterpene tetraglycoside .

HY-164477

FL442	Androgen Receptor	Cancer
FL442 is an Androgen Receptor (AR) modulator. FL442 exhibits strong inhibitory effects in AR-dependent prostate cancer cells, showing similar inhibitory efficiency to traditional antiandrogen drugs Bicalutamide (HY-14249) and Enzalutamide (HY-70002), while maintaining antiandrogenic activity against the AR mutant F876L, which is highly resistant to Enzalutamide. Pharmacokinetic studies of FL442 in mice reveal a long half-life (8 hours), good targeting (prostate tissue), and metabolic stability, and it effectively inhibits LNCaP tumor growth at low plasma concentrations (30 ng/mL) .

HY-161741

VinclozolinM2-2204	AUTOTACs Androgen Receptor	Cancer
VinclozolinM2-2204 is a androgen receptor (AR) AUTOTAC degrader, with an DC₅₀ of 200 nM in LNCaP prostate cancer cells. VinclozolinM2-2204 induces the formation of AR ⁺LC3 ⁺ autophagic membranes. VinclozolinM2-2204 can be used for the research of cancer .(Pink: AR inhibitor (HY-168296); Black: linker (HY-128833); Blue: CRBN Ligand (HY-168293))

HY-156003

HDAC-IN-64	HDAC	Cancer
HDAC-IN-64 (Compound 13) is a HDAC inhibitor. HDAC-IN-64 inhibits HDAC4/5/6/7/9 with IC₅₀s of 24, 45, 85, 31, 37 nM. HDAC-IN-64 has anti-proliferative activity and anti-migration properties on prostate cancer (PCA) cells. HDAC-IN-64 inhibits LNCaP and RWPE-1 cell growth with GI₅₀ of 0.32 and 1.1 μM respectively .

HY-162794

YCH3124	Apoptosis Deubiquitinase	Cancer
YCH3124 (compound Z33) is a USP7 inhibitor (IC₅₀=41.9 nM) with antitumor activity. YCH3124 has good in vitro antiproliferative activity against various tumor cells including LNCaP (IC₅₀=3.6 nM) and CHP-212 (IC₅₀=9.9 nM). In addition, YCH3124 disrupts cell cycle progression by restricting G1 phase and induces apoptosis in CHP-212 cells .

HY-106129

Izonsteride LY 320236	5 alpha Reductase	Endocrinology Cancer
Izonsteride (Compound LY320236) is an inhibitor of 5α-reductase (IC₅₀ = 11.6 nM for type I; 7.37 nM for type II). LY320236 inhibits the activity of steroid 5α-reductase, preventing the conversion of testosterone (T) to dihydrotestosterone (DHT). LY320236 can significantly inhibit the growth of LNCaP tumors in thymic mice without exhibiting obvious host toxicity .

HY-115282A

JNJ-63576253 1 Publications Verification TRC-253	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC) .

HY-149862

ARD-2051	PROTACs Androgen Receptor	Cancer
ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC₅₀ values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer .

HY-163510

AR/AR-V7-IN-1	Androgen Receptor	Cancer
AR/AR-V7-IN-1 (Compound 20i) is an AR/ARV7 inhibitor (IC₅₀ = 172.85 nM). AR/AR-V7-IN-1 potently inhibits cell growth with IC₅₀ values of 4.87 and 2.07 μM in the LNCaP and 22RV1 cell lines, respectively. AR/AR-V7-IN-1 exhibits effective tumor growth inhibition in the 22RV1 xenograft study. AR/AR-V7-IN-1 can be used for the research of prostate cancer .

HY-144755

MC2652	Histone Demethylase	Cancer
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells .

HY-115282

JNJ-63576253 free base TRC-253 free base	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) free base is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 free base can be used for the research of castration-resistant prostate cancer (CRPC) .

HY-N3816

ent-17-Hydroxykaur-15-en-19-oic acid	Others	Others
ent-17-Hydroxykaur-15-en-19-oic acid is a ent-kaurene diterpene that can be isolated from the leaves of Laetia thamnia L.. ent-17-Hydroxykaur-15-en-19-oic acid was cytotoxic to human prostate LNCaP2 cells with IC₅₀ 17.63 mg/mL .

HY-N2908

Atraric acid Methyl atrarate	Androgen Receptor NO Synthase p38 MAPK NF-κB	Inflammation/Immunology Cancer
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-16079

AZD3514 3 Publications Verification	Androgen Receptor	Cancer
AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer .

HY-121619

Jacaric acid	Apoptosis	Inflammation/Immunology Cancer
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC₅₀ is 11.8 μM), LNCaP (IC₅₀ is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.

HY-N1342

Rocaglaol	Apoptosis	Cancer
Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells .

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC₅₀ of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM .

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM .

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM .

HY-113332

Myristoleic acid	Apoptosis Endogenous Metabolite	Inflammation/Immunology
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells .

HY-160777

VNPP433-3β Galeterone 3β-imidazole	Molecular Glues Androgen Receptor MNK	Cancer
VNPP433-3β is a molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β inhibits proliferation of cancer cell LNCaP, C4-2B and CWR22Rv1 with GI₅₀ of 0.2, 0.3 and 0.31 μM. VNPP433-3β exhibits good pharmacokinetic characters in CD-1 mouse and inhibits tumor growth in the CWR22Rv1 xenograft mouse model .

HY-N3999

Venuloside A ESK246	Others	Cancer
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

HY-120581

ML388	PGE synthase	Cancer
ML388 is a potent and selective hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with an IC₅₀ of 34 nM. ML388 induces PGE2 production in A549 cells and LNCaP prostate cancer cells .

HY-13626

Spisulosine ES-285	PKC	Cancer
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation .

HY-N8856

Angelol M	Others	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-13626S

Spisulosine-d3	Isotope-Labeled Compounds PKC	Cancer
Spisulosine-d₃ is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC

HY-147937

AKT-IN-13	Akt	Cancer
AKT-IN-13 (compound 4b) is a potent Akt inhibitor with IC₅₀s of 1.6 nM, 2.4 nM and 0.3 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-13 can be used for researching anticancer .

HY-157460

BRD4 Inhibitor-29	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-29 (SQ-17) is a BRD4 inhibitor, with an IC₅₀ of <100 nM. BRD4 Inhibitor-29 shows antiproliferative effect against prostate cancer cells .

HY-118091A

Bexlosteride LY300502	Others	Cancer
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .

HY-156778

Antitumor agent-120	Others	Cancer
Antitumor agent-120 (compound 1) is a flavonoid compound isolated from Kudzu root.Antitumor agent-120 has no significant inhibitory activity against LNCaP and PC3 cancer cells, with IC₅₀s >50 μM .

Cat. No.	Product Name	Target	Research Area

HY-P99274

Xentuzumab 1 Publications Verification BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody	IGF-1R	Cancer
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2908

Atraric acid Methyl atrarate	Structural Classification Microorganisms Classification of Application Fields Phenols Essence, Fragrance Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	Androgen Receptor NO Synthase p38 MAPK NF-κB
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-113332

Myristoleic acid	Structural Classification Serenoa repens Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Microorganisms Animals Ketones, Aldehydes, Acids Palmae Inflammation/Immunology Disease Research Fields	Apoptosis Endogenous Metabolite
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells .

HY-N3999

Venuloside A ESK246	Structural Classification Other Monoterpenes Terpenoids Source classification Pittosporaceae Plants Pittosporum venulosum F.Muell.	Others
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

HY-N10265

Stephacidin B	Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Alkaloid Dimers Cancer	Endogenous Metabolite
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells .

HY-N12124

Monascuspiloin Monascinol	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Akt mTOR AMPK Androgen Receptor Apoptosis Autophagy
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice .

HY-N2733

7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin	Structural Classification Leguminosae Campylotropis hirtella (Franch.) Schindl. Source classification Coumarins Phenylpropanoids Plants	Others
7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin is a coumarin, that can be isolated from campylotropis hirtella (FRANCH.) SCHINDL. 7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin inhibits PSA secretion in LNCaP cells, with an IC₅₀ of 24.2 μg/mL .

HY-129672

Thelenotoside B 25-Dihydrostichorrenoside E	Other Terpenoids Structural Classification Animals Terpenoids Source classification	Others
Thelenotoside B (25-Dihydrostichorrenoside E) shows strong cytotoxicities against five cancer cell lines as HepG2, KB, LNCaP, MCF7 and SK-Mel2 with the IC₅₀ values from 0.95 ± 0.08 to 1.90 ± 0.13 μM. Thelenotoside B is a triterpene tetraglycoside .

HY-N3816

ent-17-Hydroxykaur-15-en-19-oic acid	Structural Classification Terpenoids Source classification Diterpenoids Laetia thamnia L. Plants Salicaceae	Others
ent-17-Hydroxykaur-15-en-19-oic acid is a ent-kaurene diterpene that can be isolated from the leaves of Laetia thamnia L.. ent-17-Hydroxykaur-15-en-19-oic acid was cytotoxic to human prostate LNCaP2 cells with IC₅₀ 17.63 mg/mL .

HY-121619

Jacaric acid	Structural Classification Caprifoliaceae Ketones, Aldehydes, Acids Source classification Plants Centranthus ruber (L.) DC	Apoptosis
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC₅₀ is 11.8 μM), LNCaP (IC₅₀ is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.

HY-N1342

Rocaglaol	Structural Classification Natural Products Classification of Application Fields Source classification Aglaia odorata Lour. Plants Disease Research Fields Meliaceae Cancer	Apoptosis
Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells .

HY-13626

Spisulosine ES-285	Alkaloids Classification of Application Fields Animals Source classification Marine natural products Other marine organisms Disease Research Fields Cancer	PKC
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation .

HY-N8856

Angelol M	Structural Classification Leguminosae Campylotropis hirtella (Franch.) Schindl. Source classification Coumarins Phenylpropanoids Plants	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-N1338

Royleanone NSC 122417	Quinones Structural Classification Anthraquinones Labiatae Source classification Plants Vachellia nilotica (L.) P. J. H. Hurter & Mabb.	mTOR Akt
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells .

HY-N7510

12-O-Methylcarnosic acid 12-Methoxycarnosic acid	Structural Classification Classification of Application Fields Paramacrolobium coeruleum (Taub.) J.Léonard Source classification Plants Infection Monophenols Chrysothamnus viscidiflorus Nutt. Terpenoids Labiatae Phenols Diterpenoids Disease Research Fields Cancer	5 alpha Reductase
12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC₅₀ value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-N7510R

12-O-Methylcarnosic acid (Standard)	Structural Classification Monophenols Chrysothamnus viscidiflorus Nutt. Paramacrolobium coeruleum (Taub.) J.Léonard Terpenoids Labiatae Source classification Phenols Diterpenoids Plants	5 alpha Reductase
12-O-Methylcarnosic acid (Standard) is the analytical standard of 12-O-Methylcarnosic acid. This product is intended for research and analytical applications. 12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC₅₀ value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity .

HY-N1912

Andropanolide	Structural Classification Natural Products Andrographis paniculata (Burm. F.) Nees Acanthaceae Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	Others
Andropanolide is a natural product that exerts cytotoxicity toward carcinoma cells and significantly inhibits the overproduction of nitric oxide (NO) in Lipopolysaccharides (HY-D1056) (LPS)-stimulated RAW264.7 macrophages .

HY-133537

Hygrolidin	Infection Structural Classification Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields	Antibiotic Fungal ADC Cytotoxin
Hygrolidin is a 16-membered macrolide antibiotic produced by Streptomyces hygroscopicus D-1166. Hygrolidin has anti-fungus activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity .

HY-N2345

Procyanidin B3	Structural Classification Classification of Application Fields Source classification Plants Flavonoids other families Functional Molecules Research of Health Products Phenols Polyphenols Biflavones Disease Research Fields Cancer	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N2345R

Procyanidin B3 (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Biflavones	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-125727

Globosuxanthone A	Infection Human Gut Microbiota Metabolites Monophenols Microorganisms Xanthones Classification of Application Fields Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	Fungal
Globosuxanthone A is a dihydroxanthenone with obvious antifungal activity towards Fusarium graminearum, Fusarium solani, and Botrytis cinerea with MIC values of 4, 8, and 16 μg/mL, respectively. Anticancer activity .

Cat. No.	Product Name	Chemical Structure

HY-70002S1

Enzalutamide-d6
Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-70002S

Deutenzalutamide
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-13626S

Spisulosine-d3
Spisulosine-d₃ is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

Cat. No.	Product Name		Classification

HY-133020

ARD-266		PROTAC Synthesis
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LNCap

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products